41259-65-8

Usage

InChI:InChI=1/C10H9ClN4/c11-9-8(12)10(14-6-13-9)15-7-4-2-1-3-5-7/h1-6H,12H2,(H,13,14,15)

Upstream product

• 5413-85-4 5-amino-4,6-dichloropyridimine 
• 62-53-3 aniline 

Downstream Products

• 6334-42-5 1,9-dihydro-9-phenyl-6H-purin-6-one 
• 84762-61-8 (5-Oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-phenyl-amine 
• 122625-37-0 methyl-(9-phenyl-9H-purin-6-yl)-amine 
• 5470-25-7 6-methylsulfanyl-9-phenyl-9H-purine 
• 108990-53-0 dimethyl-(9-phenyl-9H-purin-6-yl)-amine 
• 84905-75-9 N-phenyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
• 5470-24-6 6-Chloro-9-phenyl-9H-purine 
• 70538-58-8 6-chloro-8-methyl-9-phenyl-9H-purine 
• 17466-00-1 7-chloro-3-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine 
• 1237764-74-7 6-chloro-9-phenyl-7,9-dihydro-8H-purin-8-one 
• 1427273-11-7 C₁₉H₁₇N₅O₂ 
• 417943-05-6 6-amino-9-phenyl-7H-purin-8(9H)-one 
• 1307786-15-7 3-(8,9-diphenyl-9H-purin-6-ylamino)propanal 
• 1307786-13-5 3-(8,9-diphenyl-9H-purin-6-ylamino)propan-1-ol 

Relevant academic research and scientific papers

A One-Pot Synthesis of Highly Functionalized Purines

Highly substituted purines were synthesized in good to high yields through a one-pot straightforward metal-free scalable method, using the Traube synthesis adapted to Vilsmeier-type reagents. From 5-amino-4-chloropyrimidines, new 9-aryl-substituted chloropurines and intermediates for peptide nucleic acid synthesis were prepared. Variant procedures allowing a rapid synthesis of ribonucleosides and 7-benzylpurine from 5-amidino-6-aminopyrimidines are also reported to illustrate the high potential of this versatile toolbox. This route appears to be particularly interesting in the field of nucleic acids for a direct and rapid access to various new 8-alkylpurine nucleosides.

COMPOUNDS FOR TREATING CYSTIC FIBROSIS

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).

An efficient synthesis of 4,6-substituted pyrrolo[3,2-d]pyrimidines by silver-catalyzed cyclization of acetylene amine

A silver catalyzed cyclization of acetylene amine was developed to synthesize 4,6-substituted pyrrolo[3,2-d]pyrimidine, a bioactive isosteric scaffold of purine. Starting from simple commercially available acetylenes and pyrimidines, the method was found

GLUCOSE TRANSPORT INHIBITORS

The present invention relates to chemical compounds of general formula (I), in which Z, Y1, Y2, Y3, R3, R4, R5, R6, m, and n are as given in the description and in the claims, an

GLUCOSE TRANSPORT INHIBITORS

The present invention relates to chemical compounds of general formula (I): in which RA, RB, RC, RD, m, and n are as given in the description and in the claims, and which effectively and selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

Synthetic strategies to 9-substituted 8-oxoadenines

Three synthetic routes to 9-substituted 8-oxoadenines have been studied: bromination of adenine followed by N-9-alkylation/arylation and finally hydrolysis; bromination of adenine, hydrolysis, and N-functionalization as the last step; and N-9-alkylation of adenine, halogenation, and finally hydrolysis. As long as the N-9-functional group is compatible with conditions required for introduction of the halogen, the latter strategy was the most efficient. Also, a strategy starting from 5-amino-4,6-dichloropyrimidine was found to be a very good alternative for synthesis of 9-substituted 8-oxoadenines. Supplemental materials are available for this article. Go to the publisher's online edition of Synthetic Communications1 to view the free supplemental file. Copyright Taylor & Francis Group, LLC.

ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF

A novel arylpiperazine-containing purine derivatives and a pharmaceutical composition comprising the same as an active ingredient, which are useful for preventing or treating depressive disorders, are provided.

Microwave-assisted three component one-pot synthesis of pyrimido-oxazepines

A synthetic approach toward pyrimido-oxazepine analogs was developed through the use of microwave heating. Certain analogs can be made in one step, which make this a valuable tool in the investigation of this therapeutically relevant scaffold.

Enhanced selectivity for inhibition of analog-sensitive protein kinases through scaffold optimization

The ability to inhibit any protein kinase of interest with a small molecule is enabled by a combination of genetics and chemistry. Genetics is used to modify the active site of a single kinase to render it distinct from all naturally occurring kinases. Next, organic synthesis is used to develop a small molecule, which does not bind to wild-type kinases but is a potent inhibitor of the engineered kinase. This approach, termed chemical genetics, has been used to generate highly potent mutant kinase-specific inhibitors based on a pyrazolopyrimidine scaffold. Here, we asked if the selectivity of the resulting pyrazolopyrimidines could be improved, as they inhibit several wild-type kinases with low-micromolar IC50 values. Our approach to improve the selectivity of allele-specific inhibitors was to explore a second kinase inhibitor scaffold. A series of 6,9-disubstituted purines was designed, synthesized, and evaluated for inhibitory activity against several kinases in vitro and in vivo. Several purines proved to be potent inhibitors against the analog-sensitive kinases and exhibited greater selectivity than the existing pyrazolopyrimidines.

Tricyclic azepine derivatives: Pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors

A novel class of pyrimido[4,5-b]-1,4-benzoxazepines is described as inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase. Two compounds display potent EGFR inhibitory activity of less than 1 μM in cellular phosphorylation assays (IC50 0.47-0.69 μM) and are highly selective against a small kinase panel. Such compounds demonstrate anti-EGFR activity within a class that is different from any known EGFR inhibitor scaffolds. They also provide a basis for the design of kinase inhibitors with the desired selectivity profile.